# To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males

> **NCT06692465** · PHASE2 · COMPLETED · sponsor: **Suzhou Kintor Pharmaceutical Inc,** · enrollment: 180 (actual)

## Conditions studied

- Alopecia
- Male Pattern Hair Loss

## Interventions

- **DRUG:** GT20029 Tincture
- **DRUG:** GT20029 matching placebo

## Key facts

- **NCT ID:** NCT06692465
- **Lead sponsor:** Suzhou Kintor Pharmaceutical Inc,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-13
- **Primary completion:** 2023-12-14
- **Final completion:** 2024-06-30
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06692465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06692465, "To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06692465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*